



The Board of Directors confirms Leon Van Rompay as Mithra's CEO

Liege, Belgium, 15 October 2021 – 17:45 CEST – The Board of Directors of Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, has confirmed the appointment of Mr. Leon Van Rompay as Chief Executive Officer of the company, a position he held ad interim since February 04, 2021.

Last February¹, the Board of Directors accepted that François Fornieri takes a step back as CEO for a maximum period of 12 months, following his indictment in the context of an external file not related to Mithra. The Board of Directors then decided to appoint Leon Van Rompay as CEO ad interim until further notice, François Fornieri remaining at the disposal of the CEO ad interim.

Since then, Mithra succeeded in taking up many challenges including the launch of its first estetrol-based product, Estelle[®] contraceptive pill, on the main world markets. The current management has made significant progress in several strategic and operational areas, being able to rely on the solid experience of Mr. Van Rompay in the pharmaceutical sector, as well as on the multidisciplinary expertise of the new Board of Directors in place since May of this year and chaired by Mr. Ajit Shetty.

"I can only be delighted by the reliability and determination shown by all Mithra employees and I thank them for it", notes François Fornieri, founder and reference shareholder of Mithra. "On the basis of this excellent record, I have therefore decided, in consultation with the Board of Directors, to reiterate my confidence in Mr. Van Rompay in his capacity as CEO of Mithra and to remain on the sidelines of my executive functions, as long as the legal case related to insider trading is pending. As the founder and principal shareholder of the company, I will continue to fully fulfill my role as a member of the Board of Directors and to support the strategy of the company from this seat. I have full confidence in the team in place to turn Mithra's potential into success."

Following the decision of Mr. Fornieri, Mithra's Board of Directors confirmed Leon Van Rompay as Chief Executive Officer.

"I am very honored by the trust placed by Mr. Fornieri and the entire Board of Directors", reacts Leon Van Rompay, CEO of Mithra. "Mithra can pride itself on having successfully completed the ultimate challenge for any biotech: succeed in launching an innovative molecule on an international scale, thanks to Mr. Fornieri's vision and the strong commitment of all our teams over the past 20 years. I am determined to bring the second chapter of this adventure to a successful conclusion as well as to bring Mithra closer to its promising ambitions."

¹ [Mithra's Press release 04/02/2021](#)

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

The logo consists of a teal circle containing the words "News Alerts" in white, stacked vertically.

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[LinkedIn](#) • [Twitter](#) • [Facebook](#)